UBS Group Increases Oruka Therapeutics (NASDAQ:ORKA) Price Target to $75.00

Oruka Therapeutics (NASDAQ:ORKA) had its target price raised by stock analysts at UBS Group from $50.00 to $75.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price would indicate a potential upside of 33.49% from the stock’s previous close.

Several other equities analysts have also weighed in on the company. Wedbush restated an “outperform” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, March 13th. Piper Sandler initiated coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target for the company. BTIG Research reissued a “buy” rating and set a $73.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 13th. Guggenheim restated a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a report on Friday, March 13th. Finally, Stifel Nicolaus upped their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.10.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA traded up $2.87 during trading on Monday, reaching $56.18. The company had a trading volume of 1,463,003 shares, compared to its average volume of 576,039. The firm’s fifty day moving average is $36.96 and its 200 day moving average is $30.74. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $58.99. The firm has a market capitalization of $2.78 billion, a PE ratio of -30.05 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.16. Equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the sale, the insider owned 33,377 shares of the company’s stock, valued at $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 23,765 shares of company stock worth $849,575 in the last quarter. Corporate insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Seven Fleet Capital Management LP acquired a new stake in Oruka Therapeutics in the fourth quarter worth about $159,000. Invesco Ltd. raised its holdings in Oruka Therapeutics by 777.1% during the 4th quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock worth $4,338,000 after purchasing an additional 126,803 shares during the last quarter. Virtus Investment Advisers LLC bought a new stake in Oruka Therapeutics during the 4th quarter worth about $267,000. Finally, RTW Investments LP raised its stake in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after buying an additional 112,499 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.